

Romiplostim for the treatment of chronic immune or idiopathic thrombocytopenic purpura

<http://guidance.nice.org.uk/TA/Wave17/16>

Dear Consultees and Commentators,

The NICE Technology Appraisal Committee were due to discuss this appraisal at their meeting on 7 January 2010.

The manufacturer of romiplostim are submitting a Patient Access Scheme. This scheme will need to be formally considered by the Department of Health. The Evidence Review Group will then need to critique the manufacturer's assessment of the scheme.

Consequently it will not be possible for the Committee to discuss this appraisal on 7 January. We will contact you again to let you know when this appraisal will be discussed.

If you have any questions, please contact me.

Kind regards,

Jeremy

Jeremy Powell

Technology Appraisal Project Manager
National Institute for Health and Clinical Excellence
MidCity Place | 71 High Holborn | London WC1V 6NA | United Kingdom
Tel: 44 (0)20 7045 2248 | Fax: 44 (0)20 7061 9830